1Jia-he Tian,Jin-ming Zhang,Qing-tian Hou,Qiao-hong Oyang,Jian-min Wang,Zhao-sheng Luan,Ling Chuan,Yi-jie He.Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China[J].European Journal of Nuclear Medicine.1999(1)
2Lluis Berna,Ignasi Carrio,Carmen Alonso,Josep Ferré,Montserrat Estorch,Gustavo Torres.Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain[J].European Journal of Nuclear Medicine.1995(10)
3Lewington VJ,McEwan Al,Ackery DM,et al.A prospective, randomised double-blind crossover study to examine the efficacy of strontium 89 in pain palliation in patients with advanced prostate cancer metastatic to bone[].European Journal of Cancer.1991
4Edwards GK,Santoro J,Taylor A.Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89[].The Journal of Nuclear Medicine.1994
5Laing AH,Ackery DM,Bayly RJ,et al.Strontium-89 chloride for pain palliation in prostatic skeletal malignancy[].British Journal of Radiology.1991
6Turner JH,Claringbold PG,Hetherington EL,et al.A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases[].Journal of Clinical Oncology.1989
7Lovera C,Massardo T,Galleguillos MC,et al.Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylene phosphate[].Revista Medica de Chile.1998
8Serafini AN,Houston SJ,Resche I,et al.Palliation of pain associated with metastatic bone cancer using samsrium-153 lexidronam: a double-blind placebo-controlled clinical trial[].Journal of Clinical Oncology.1998
9Quilty PM,Kirk D,Bolger JJ,et al.A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer[].Radiotherapy and Oncology.1994
10Collins C,Eary JF,Donaldson G,et al.Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase Ⅰ/Ⅱ trial[].The Journal of Nuclear Medicine.1993
